Safety and Efficacy of Sitagliptin Added to Insulin Therapy for Type 2 Diabetes
NCT ID: NCT01855087
Last Updated: 2013-05-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
OBSERVATIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treatment With Sitagliptin in Non-obese Japanese Patients With Type 2 Diabetes Mellitus
NCT01642108
An Investigational Drug in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (0431-028)(COMPLETED)
NCT00095056
Effects of Sitagliptin on Type 2 Diabetes Mellitus Patients on Treatment With Metformin and Insulin
NCT01341717
Sitagliptin Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus
NCT00337610
Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Participants With Type 2 Diabetes Mellitus (MK-0431-251)
NCT01189890
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* addition of sitagliptin to insulin therapy
* aged 20 years or older
* HbA1c of 6.9% or higher (NGSP) at the time of adding sitagliptin
Exclusion Criteria
* severe ketosis, diabetic coma, and/or precoma within 6 months before sitagliptin administration
* sever infection and/or severe trauma, and/or patients who are scheduled to undergo / have recently underwent surgery
* severe renal dysfunction (serum creatinine \[mg/dL\]: 2.5 or higher for men; 2.0 or higher for women)
* ongoing treatment with glinide(s)
* judgment as ineligible for the study by the attending physician
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Japan Kidney Foundation
OTHER
Kanagawa Physicians Association
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ikuro Matsuba
Chairperson
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Takai Naika Clinic
Kamakura, Kanagawa, Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
R875
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.